BD Partners with Opentrons to Revolutionize Single-Cell Multiomics Research Automation
- BD partners with Opentrons to integrate automation in single-cell multiomics research, enhancing efficiency and scalability.
- The collaboration aims to streamline workflows, reducing human error and improving research reliability in oncology and immunology.
- BD's Rhapsody System will gain an automation-compatible module for key experimental steps, making advanced sequencing more accessible.
BD Partners with Opentrons to Enhance Single-Cell Multiomics Research
Becton, Dickinson and Company (BD), a leading name in global medical technology, announces a significant partnership with Opentrons Labworks, Inc., a pioneer in accessible lab automation. This collaboration focuses on integrating robotic liquid-handling capabilities into BD’s single-cell multiomics instruments, particularly the BD Rhapsody® HT Xpress System. The aim is to enhance the efficiency and scalability of studies involving millions of cells, which is critical for advancing research in oncology and immunology. By automating key experimental procedures, BD and Opentrons seek to streamline workflows, thereby accelerating the pace of disease research and drug development.
Dr. Ranga Partha, Vice President and General Manager of Global Marketing and Strategic Growth Areas at BD Biosciences, underscores the transformative potential of this integration. He states that providing scientists with automated solutions facilitates faster and more reproducible insights into complex biological information at the cellular level. The collaboration will merge the capabilities of the BD Rhapsody™ System with Opentrons’ Flex® platform, which allows for hands-free workflows during single-cell multiomics experiments. This integration not only enhances operational efficiency but also reduces the potential for human error, thus improving the reliability of research outcomes.
A key component of this collaboration is the development of an automation-compatible module for the BD Rhapsody™ System. This module aims to automate critical steps such as next-generation sequencing library preparation and cell capture. Dr. James Atwood, CEO of Opentrons Labworks, highlights the complementary strengths of both companies, remarking that their combined expertise will make advanced single-cell sequencing more accessible and cost-effective for research laboratories. This partnership signals a significant step towards improving the capabilities of laboratories engaged in both basic and translational research, with early access opportunities for interested parties expected to be announced soon.
In addition to enhancing research capabilities, this partnership reflects a broader trend in the medical technology industry towards automation and precision. By integrating automation into complex scientific workflows, BD and Opentrons are positioning themselves at the forefront of innovation in laboratory technology. The collaboration not only promises to facilitate groundbreaking research but also aims to lower the barriers for laboratories looking to adopt advanced techniques in single-cell analysis.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

